Roche CEO Thomas Schinecker explained three reasons for not joining the recent Big Pharma acquisition spree:
wariness of high interest rates and additional debt, lack of urgent patent cliffs with 19 medicines potentially launching by decade's end, and commitment to paying acceptable prices without overpaying.1
Roche has financed recent deals with earned money, avoiding debt amid high interest rates.1
Upcoming launches include obesity assets like enicepatide and petrelintide, MS therapy fenebrutinib, and breast cancer drug giredestrant.1
Sources:
1. https://www.fiercebiotech.com/biotech/debt-acceptable-prices-roche-ceo-lists-3-reasons-sitting-out-big-pharma-deal-spree